Lithium response in bipolar disorder: Genetics, genomics, and beyond.
Genome-wide association studies
Mood-stabilizer
Polygenic risk score
iPSC
Journal
Neuroscience letters
ISSN: 1872-7972
Titre abrégé: Neurosci Lett
Pays: Ireland
ID NLM: 7600130
Informations de publication
Date de publication:
10 08 2022
10 08 2022
Historique:
received:
01
04
2022
revised:
01
07
2022
accepted:
06
07
2022
pubmed:
12
7
2022
medline:
20
7
2022
entrez:
11
7
2022
Statut:
ppublish
Résumé
Lithium is an effective mood stabilizer in bipolar disorder (BD). There is, however, high variability in treatment response to lithium and only 20-30% of individuals with BD are excellent responders. This subgroup has been shown to have specific phenotypic characteristics, and family studies have implicated genetics as an important factor. However, candidate gene studies did not find evidence for major effect genes. Genome-wide association studies (GWAS) have emphasized that lithium response is a polygenic trait. GWAS based on larger sample sizes and non-European ancestries are likely to shed light on the genomic architecture of this trait. Furthermore, induced pluripotent stem cells, transcriptomics, epigenetics, the integration of multiple omics data, and their combination with advanced machine learning techniques hold promise for the understanding of the complex biological underpinnings of lithium treatment response.
Identifiants
pubmed: 35817312
pii: S0304-3940(22)00347-0
doi: 10.1016/j.neulet.2022.136786
pii:
doi:
Substances chimiques
Lithium Compounds
0
Lithium
9FN79X2M3F
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136786Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.